Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer
Clinical trial NCT07638631 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07638631
- Sponsor
- Chen Lizhu
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-15
- Primary completion
- 2028-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.